2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
Biotech stocks got pummeled in 2022. Valuations across the small- and mid-cap biotech landscape cratered last year as the concept of "deep value" got zeroed out by rising interest rates and a general flight to safety.
As a result, there are scores of developmental biotech companies trading at a fraction of their net cash positions right now. This tsunami of selling in the space, though, has seemingly created some tremendous opportunities for investors with a long-term mindset.
Image source: Getty Images.
Source Fool.com
